Methods and compositions for the modulation of cell proliferation and wound healing

• US 6,063,396 A
• Filed: 02/12/1996
• Issued: 05/16/2000
• Est. Priority Date: 10/26/1994
• Status: Expired due to Fees

• Current Assignee: Houston Biotechnology, Inc. (Bristol-Myers Squibb Company)
• Original Assignee: Houston Biotechnology, Inc. (Bristol-Myers Squibb Company)
• Inventors: Kelleher, Peter Joseph
• Primary Examiner(s): Azpuru, Carlos A.
• Application Number:
  US08/600,381
• Time in Patent Office: 1,555 Days
• Field of Search: 424/427, 424/428, 514/912
• US Class Current: 424/428
• CPC Class Codes: A61F 2/1613 having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
• CPC Class Codes: A61K 47/6957 the form being a device or a kit, e.g. stents or microdevices
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 27/28 Materials for coating prostheses
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

Implants which are capable of sustained release of a cell proliferation modulating agent, together with methods for their preparation and use, are provided. The proliferation modulating agent is associated either covalently or non-covalently with the material from which the implant is prepared, generally a biologically inert polymer which is physiologically compatible. The implants are implanted in the tissue, and the drug is released such that the drug is substantially retained within the implant region. The device can be used to inhibit cellular proliferation around the implant. The device can be provided as a sterile kit, preferably in a form suitable for immediate use.

Claims

1. An implant comprising:

at least one agent which modulates proliferation of target cells, wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of;

a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue.

2. The implant according to claim 1, wherein the rate at which said agent is released is controlled so as to restrict said agent to a localized region of said tissue.

3. The implant according to claim 1, wherein said rate is controlled by the molar substitution ratio of said agent to the number of said reactive groups on said polymer.

4. The implant of claim 1, wherein said reactive group is selected from the group consisting of carboxyl, amino, hydroxyl, and hydrazido.

5. The implant of claim 1, wherein said polymer comprises a polysaccharide.

6. The implant of claim 5, wherein said polysaccharide is hyaluronan or a salt of hyaluronan.

7. The implant of claim 1, wherein said polymer is selected from the group consisting of carboxymethylcellulose, polymethylmethacrylate, hydroxypropylmethylcellulose, hyaluronan, nylon, and silicone.

8. The implant of claim 1, wherein said agent inhibits target cell proliferation.

9. The implant of claim 8, wherein said agent comprises an antimitotic.

10. The implant of claim 9, wherein said antimitotic is selected from the group consisting of anthracycline, daunomycin, mitomycin C, and doxorubicin.

11. The implant of claim 8, wherein said agent comprises an antimetabolite.

12. The implant of claim 11, wherein said antimetabolite is 5-flourouracil.

13. The implant of claim 8, wherein said agent is a toxin.

14. The implant of claim 13, wherein said toxin is ricin.

15. The implant of claim 1, wherein said target cells are fibroblast cells.

16. The implant of claim 1, wherein said target cells are epithelial cells.

17. The implant of claim 1, wherein said agent and polymer are bound by a covalent bond.

18. The implant of claim 2, wherein said localized region is a filtration site.

19. The implant of claim 1, wherein said localized region is a lens capsule equatorial region.

20. The implant of claim 1, wherein said localized region is an abdominal surgery site or a pelvic surgery site.

25. A method for modulating proliferation of target cells in a localized region of the eye, said method comprising:

contacting a localized region of the eye with an ocular implant according to claim 17.

26. The method of claim 25, wherein said localized region of the eye is a filtration site.

27. The method of claim 25, wherein said target cells are lens epithelial cells.

28. The method of claim 25, wherein said contacting is with an implant or through injection at a surgery site.

29. The method of claim 25, wherein said contacting is at the time of ocular surgery.

30. The method of claim 25, wherein said ocular surgery is cataract surgery or glaucoma filtering surgery.

31. A method of controlling formation of tissue adhesion sites, said method comprising:

contacting tissue at a surgery site with an implant according to claim 1.

33. The implant of claim 17, wherein said covalent bond comprises a hydrazone linkage.

21. An ocular implant comprising:

at least one agent which modulates proliferation of target cells bound wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of;

a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue, and wherein said agent is selected from the group consisting of daunomycin, mitomycin C, doxorubicin, and wherein said polymer is selected form the group consisting of hyaluronic acid, polymethylmethacrylate, hydroxypropylmethylcellulose, carboxymethylcellulose, silicone and nylon.

22. The ocular implant of claim 21 which is a membrane.

23. The ocular implant of claim 21, wherein said implant is selected from the group consisting of an intraocular lens, a drainage shunt, a prosthesis, and a lens capsular loop.

24. The ocular implant according to claim 21 in a form suitable for injection.

32. A method of making a polymer implant comprising at least one agent which modulates proliferation of target cells bound wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of:

a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, said method comprising;

contacting a polymer having a sufficient number of reactive groups with a sufficient amount of an agent which modulates proliferation of target cells to form a bond which is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue.